Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.

Hornberger J, Lyman GH, Chien R, Meropol NJ.

Value Health. 2012 Dec;15(8):1014-21. doi: 10.1016/j.jval.2012.07.012. Epub 2012 Nov 7.

2.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
3.

Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer.

Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J.

Pharmacoeconomics. 2014 Dec;32(12):1231-43. doi: 10.1007/s40273-014-0207-1.

4.

Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.

Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z.

Pharmacoeconomics. 2014 Mar;32(3):235-43. doi: 10.1007/s40273-013-0065-2.

PMID:
23709451
5.
6.

Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.

Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.

Cancer. 2007 Mar 15;109(6):1082-9.

7.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

8.

Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.

Lerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, Chindavijak S, Khuhaprema T, Tantai N, Teerawattananon Y.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):687-700. doi: 10.1586/14737167.2015.972379. Epub 2014 Oct 18.

PMID:
25327502
9.

Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.

Ayvaci MU, Shi J, Alagoz O, Lubner SJ.

Med Decis Making. 2013 May;33(4):521-32. doi: 10.1177/0272989X12470755. Epub 2013 Jan 11.

11.

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.

Value Health. 2011 Jul-Aug;14(5):647-51. doi: 10.1016/j.jval.2011.01.010. Epub 2011 Jun 22.

12.

Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.

Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.

Pharmacoeconomics. 2009;27(7):597-608. doi: 10.2165/11310110-000000000-00000.

PMID:
19663530
13.

Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.

Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.

Value Health. 2012 Mar-Apr;15(2):255-60. doi: 10.1016/j.jval.2011.10.006. Epub 2011 Dec 15.

14.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Hall PS, McCabe C, Stein RC, Cameron D.

J Natl Cancer Inst. 2012 Jan 4;104(1):56-66. doi: 10.1093/jnci/djr484. Epub 2011 Dec 2.

PMID:
22138097
15.
16.

Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.

Ercolani G, Cucchetti A, Cescon M, Peri E, Brandi G, Del Gaudio M, Ravaioli M, Zanello M, Pinna AD.

Eur J Cancer. 2011 Oct;47(15):2291-8. doi: 10.1016/j.ejca.2011.05.014. Epub 2011 Jun 7. Review.

PMID:
21652204
17.

Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.

Cartwright T, Chao C, Lee M, Lopatin M, Bentley T, Broder M, Chang E.

Curr Med Res Opin. 2014 Feb;30(2):321-8. doi: 10.1185/03007995.2013.855183. Epub 2013 Nov 7.

PMID:
24127781
18.

Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.

Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.

World J Gastroenterol. 2014 Dec 21;20(47):17976-84. doi: 10.3748/wjg.v20.i47.17976.

19.

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR.

Oncologist. 2014 May;19(5):492-7. doi: 10.1634/theoncologist.2013-0401. Epub 2014 Apr 7.

20.

Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.

Roth JA, Billings P, Ramsey SD, Dumanois R, Carlson JJ.

Oncologist. 2014 May;19(5):466-76. doi: 10.1634/theoncologist.2013-0357. Epub 2014 Apr 7.

Supplemental Content

Support Center